# Fidia Farmaceutici s.p.a. clinical trials: 32 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials with Fidia Farmaceutici s.p.a. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Fidia Farmaceutici s.p.a.: 32 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/fidia-farmaceutici-s-p-a

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 9, 2026 | NCT07520708 | Performance and Safety of HyalganBio® Intra-Articular Injections as Add-On to Physical Exercise for Symptomatic Glenohumeral Osteoarthritis | Fidia Farmaceutici s.p.a. | Not applicable | Active not recruiting | Glenohumeral Osteoarthritis | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07520708) |
| February 24, 2026 | NCT07431385 | Performance and Safety of IRIDIUM GARZE in Blepharitis or Blepharconjunctivitis Adjuvant Treatment | Fidia Farmaceutici s.p.a. | Not applicable | Completed | Blepharitis, Blepharoconjunctivitis | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07431385) |
| April 10, 2025 | NCT06922136 | Evaluation of the Performance and Safety of Hyalo Gyn® Gel Compared to Placebo in Postmenopausal Breast Cancer Survivors | Fidia Farmaceutici s.p.a. | Not applicable | Active not recruiting | Vulvo Vaginal Atrophy | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06922136) |
| July 30, 2024 | NCT06528600 | Comparative Study of Two Hyaluronic Acid Formulation in the Management of Knee Osteoarthritis | Fidia Farmaceutici s.p.a. | Not applicable | Completed | Osteoarthritis, Knee | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06528600) |
| January 18, 2024 | NCT06210373 | Assessment of Efficacy and Safety of the Use of Two Eye Gel Products Containing 5% Dexpanthenol in Patients With Moderate to Severe Dry Eye... | Fidia Farmaceutici s.p.a. | Not applicable | Completed | Dry Eye Disease | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06210373) |
| January 5, 2024 | NCT06190054 | Evaluation of Performance and Safety of Eye Drops With Hydroxypropyl-methylcellulose and Inositol in Drye Eye Disease | Fidia Farmaceutici s.p.a. | Not applicable | Completed | Dry Eye Disease Associated to Asthenopia and Accommodative Effort in Video Display Terminal Users | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06190054) |
| January 5, 2024 | NCT06190028 | Evaluation of Performance and Safety of Carbopol 980 NF 0.2%- Based Medical Device in the Management of Patients With Glaucomar or Ocular... | Fidia Farmaceutici s.p.a. | Not applicable | Terminated | Dry Eye Syndrome, Glaucoma and Concomitant Dry Eye Syndrome, Ocular Hypertension and Concomitant Dry Eye Syndrome... | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06190028) |
| January 3, 2024 | NCT06189456 | Evaluation of Performance and Safety of Eye Drops With Hyaluronic Acid 0.30% and 0.15% | Fidia Farmaceutici s.p.a. | Not applicable | Completed | Dry Eye Syndrome (DES) | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06189456) |
| November 2, 2023 | NCT06113783 | Assessment of Efficacy of a Single Intra-articular Injection of HYALUBRIX 60 in Knee Osteoarthritis | Fidia Farmaceutici s.p.a. | Not applicable | Unknown | Knee Osteoarthritis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06113783) |
| October 31, 2023 | NCT06108999 | Management of Acute and Chronic Wounds With Hyaluronic Acid | Fidia Farmaceutici s.p.a. | Not applicable | Unknown | Wound Heal, Wound; Foot | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06108999) |
| October 27, 2023 | NCT06103812 | Evaluate Performance and Safety of Hyalo4 Skin in Acute and Chronic Wounds | Fidia Farmaceutici s.p.a. | Observational | Unknown | Wound Heal | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06103812) |
| October 5, 2023 | NCT06069453 | Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC. | Fidia Farmaceutici s.p.a. | Not applicable | Terminated | Non-muscle Invasive Bladder Cancer (NMIBC) | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06069453) |
| October 2, 2023 | NCT06062771 | Efficacy and Safety of the Use of Ophthalmic Viscosurgical Devices (OVD) FIDIAL PLUS vs IAL®-F During Cataract Surgery | Fidia Farmaceutici s.p.a. | Not applicable | Completed | Cataract | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06062771) |
| August 27, 2021 | NCT05024773 | Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) | Fidia Farmaceutici s.p.a. | Phase 3 | Active not recruiting | Bladder Carcinoma in Situ (CIS) | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05024773) |
| July 26, 2021 | NCT04976088 | Clinical Trial With Diclofenac Sodium Medicated Plaster in Patients With Impact Injuries of the Limbs | Fidia Farmaceutici s.p.a. | Phase 3 | Completed | Trauma Injury, Inflammation | 214 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04976088) |
| July 23, 2021 | NCT04975724 | Safety of Liposom With Citalopram in Elderly Patients With Major Depressive Disorder | Fidia Farmaceutici s.p.a. | Phase 4 | Unknown | Major Depressive Disorder | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04975724) |
| June 23, 2021 | NCT04936204 | Clinical Investigation to Evaluate the Safety and Performance of ConnettivinaBio Plus Cream Compared to ConnettivinaBio Cream in the... | Fidia Farmaceutici s.p.a. | Not applicable | Unknown | Wounds | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04936204) |
| March 15, 2021 | NCT04798703 | Study of ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID) | Fidia Farmaceutici s.p.a. | Phase 1 | Completed | Bladder Carcinoma in Situ (CIS) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04798703) |
| February 16, 2021 | NCT04757038 | An Open Label, Randomized-controlled Trial to Assess Efficacy Safety of HYALODISC With Physical Exercise Program | Fidia Farmaceutici s.p.a. | Not applicable | Unknown | Degenerative Disc Disease(DDD) | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04757038) |
| December 10, 2020 | NCT04661826 | ONCOFID-P-B in the Intravescical Therapy of Patients With Non-muscle Invasive Cancer of the Bladder. | Fidia Farmaceutici s.p.a. | Phase 2 | Completed | Non-Invasive Papillary Carcinoma of Bladder | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04661826) |
| December 10, 2020 | NCT04661111 | Efficacy and Safety of Hymovis ONE® (32mg/4ml) Intrarticular Injection in Active Patients With Knee Overuse Syndrome | Fidia Farmaceutici s.p.a. | Not applicable | Completed | Knee Osteoarthritis | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04661111) |
| December 3, 2020 | NCT04652752 | Clinical Investigation to Evaluate the Safety and Efficacy of Dressing CONNETTIVINA HI TECH in the Management of Superficial Cutaneous... | Fidia Farmaceutici s.p.a. | Not applicable | Terminated | Superficial Cutaneous Lesions | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04652752) |
| November 4, 2020 | NCT04614415 | Clinical Investigation to Evaluate the Performance of Hyaluronic Acid for the Treatment of Hypertrophic Scars | Fidia Farmaceutici s.p.a. | Not applicable | Unknown | Hypertrophic Scar | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04614415) |
| October 14, 2020 | NCT04585334 | Effectiveness of Tricortin 1000 in Patients Affected by Chronic Low Back Pain | Fidia Farmaceutici s.p.a. | Phase 4 | Unknown | Low Back Pain, Mechanical | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04585334) |
| October 14, 2020 | NCT04585321 | Comparative Bioavailability and Local Tolerability of Two Topical Diclofenac Plasters Applied Once and Twice a Day | Fidia Farmaceutici s.p.a. | Phase 1 | Completed | Bioequivalence Study | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04585321) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 3 |
| Phase 4 | 2 |
| Not applicable | 23 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 17 |
| Unknown | 9 |
| Terminated | 3 |
| Active not recruiting | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Osteoarthritis, Knee | 6 |
| Dry Eye Syndromes | 3 |
| Osteoarthritis | 2 |
| Glaucoma | 1 |
| Ocular Hypertension | 1 |
| Intervertebral Disc Degeneration | 1 |
| Depressive Disorder, Major | 1 |
| Cataract | 1 |
| Wounds and Injuries | 1 |
| Cicatrix, Hypertrophic | 1 |
| Urinary Bladder Neoplasms | 1 |
| Foot Injuries | 1 |
| Accidental Injuries | 1 |
| Inflammation | 1 |
| Blepharitis | 1 |
| Non-Muscle Invasive Bladder Neoplasms | 1 |
| Pain | 1 |
| Low Back Pain | 1 |
| Bronchiolitis Obliterans Syndrome | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Comfort food restaurants in the United States](https://specstream.ai/data/businesses/comfort-food-restaurants/united-states)
- [Telecommunications services in the United States](https://specstream.ai/data/businesses/telecommunications-services/united-states)
- [Lawn care companies in the United States](https://specstream.ai/data/businesses/lawn-care-companies/united-states)
- [Collection agencies in the United States](https://specstream.ai/data/businesses/collection-agencies/united-states)
- [Tax law firms in the United States](https://specstream.ai/data/businesses/tax-law-firms/united-states)
- [Laser cutting companies in the United States](https://specstream.ai/data/businesses/laser-cutting-companies/united-states)
